




This update comprises six important topics under neurocritical care that require reevaluation. For post-cardiac
arrest brain injury, the evaluation of the injury and its corresponding therapy, including temperature modulation,
is required. Analgosedation for target temperature management is an essential strategy to prevent shivering and
minimizes endogenous stress induced by catecholamine surges. For severe traumatic brain injury, the diverse
effects of therapeutic hypothermia depend on the complicated pathophysiology of the condition. Continuous
electroencephalogram monitoring is an essential tool for detecting nonconvulsive status epilepticus in the intensive care
unit (ICU). Neurocritical care, including advanced hemodynamic monitoring, is a fundamental approach for
delayed cerebral ischemia following subarachnoid hemorrhage. We must be mindful of the high percentage of
ICU patients who may develop sepsis-associated brain dysfunction.
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Introduction
Neurocritical care is the intensive care provided to
patients with severe neurological and neurosurgical con-
ditions. It provides the interface between the brain and
other organ systems. Neurocritical care provides com-
prehensive medical and specialized neurological support
for patients with life-threatening neurological diseases
by integrating and balancing the management of both
the brain and the body [1]. The aim of this review is to
provide an update on neurocritical care in adults.
Review
Post-cardiac arrest brain injury and targeted temperature
management
Overview
Post-cardiac arrest brain injury is a syndrome of acute
global brain injury resulting from a critical reduction in
blood flow or oxygen and nutrient supply. Its most com-
mon clinical features include disorders pertaining to
consciousness (coma and vegetative status), seizures, and
myoclonus. Targeted temperature management (TTM;
32–36 °C) and diagnosing/treating seizures are essential
elements of post-resuscitation care for global ischemic
brain injury. Furthermore, careful evaluation and manage-
ment of other organ injuries (myocardial dysfunction,
aspiration pneumonia, bowel ischemia, acute kidney
injury, and disordered glucose regulation) is required.
Hematologic and coagulation disorders are also recog-
nized to be associated with post-cardiac arrest syndrome
(PCAS) [2]; however, they are not well described and fully
understood.
Regarding the temperature control, the term “TTM” is
recommended to emphasize the importance of defining
a complete temperature profile [3]. The specific tem-
perature ranges of TTM (32–36 °C) include therapeutic
hypothermia (TH; 32–34 °C) and fever control (normo-
thermia, approximately 36 °C).
Optimal targeted temperature
TH (32–34 °C) [4], according to the positive neuropro-
tective results of randomized controlled trials (RCTs)
[5, 6], is recommended for comatose (i.e., lack of
meaningful response to verbal commands) adult pa-
tients who achieve return of spontaneous circulation
(ROSC) after out-of-hospital cardiac arrest. However, a
recently published RCT concluded that in comatose
survivors or in those who sustained out-of-hospital
cardiac arrest, normothermia (36 °C) management pro-
vided the same benefits as those provided by TH (33 °C)
[7]. A reason for this discrepancy is the differences in the
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study design [8] of TTM trial [7]: larger deviation in body
temperature, neurological evaluation performed 72 h (too
early) after the intervention, and relatively low incidence
of favorable neurological outcome [9]. Another reason for
this discrepancy may be that the severity of organ injury,
including the brain, varies among studies and patients be-
cause of the absence of an established modality enabling
proper evaluation.
Optimal target temperature during TTM corresponding
to the post-cardiac arrest brain injury remains to be evalu-
ated, although 32–36 °C has been generally adopted [5–7].
A small pilot RCT comparing 32 and 34 °C management
found that 32 °C management has benefits pertaining to
neurologically intact survival [10]. A recent study [11]
showed that PCAS patients with a resuscitation inter-
val of <30 min may be candidates for TH using a target
temperature of <34 °C. Regardless of the target tem-
perature, temperature control remains a key aspect in
the management of post-cardiac arrest patients [12]. If
a temperature of 36 °C is selected, shivering is likely to be
more pronounced because the patients’ thermoregulatory
defenses, which are partly suppressed at 32–33 °C, will be
much more active at 36 °C [13]. Specific target temperature
interventions tailored for individual patients await further
research.
Evaluation of brain damage
To date, the degree of damage in the brain and other
organs of TH candidates has been estimated using com-
binations of several indirect factors, such as bystander
cardiopulmonary resuscitation, witness, initial rhythm,
and downtime [5–7]. Moreover, brain damage after ROSC
varies among patients despite their comatose status [14].
Although there have been three studies [7, 14, 15]
reporting on the admission Glasgow Coma Score (GCS)
motor score as a measure of the efficacy of TH in coma-
tose cardiac arrest survivors, the association between
GCS motor score and neurologic outcome remains un-
known. Two recent studies examined the GCS motor
scores immediately after ROSC (day 0), and the outcome
suggested that the score is an independent predictor of
good neurologic outcome [16] and that no significant
differences of neurologic outcome at 30 days after hos-
pital admission was observed between mild TH and con-
trol in the subgroup of GCS motor score 5 or 6 [17, 18].
These data show that initial GCS motor score examin-
ation immediately after ROSC can at least provide base-
line objective prognostic data for decisions by healthcare
professionals.
The full outline of unresponsiveness (FOUR) score
includes additional information not assessed by GCS,
including brain stem reflex, visual tracking, breathing
patterns, and respiratory drive (Table 1) [19]. An early,
novel illness severity score using FOUR and serial organ
function assessment scores at hospital or intensive care
unit (ICU) arrival predicts outcome after cardiac arrest
[20, 21].
Shivering may reflect the degree of brain damage.
Data from a recent study shows that patients who ex-
perienced shivering (60 %) because of the induction of
TH for PCAS had a significantly better rate of favor-
able (cerebral performance categories 1–2) neurologic
outcome at discharge from the hospital compared to
patients who did not experience shivering (36 %) [22].
Conversely, no shivering after the induction of hypo-
thermia or spontaneous hypothermia prior to the in-
duction of hypothermia has been associated with a
poor outcome [23]. Shivering may be a sign of a less-
impaired thermoregulatory pathway. Neurological signs
such as GCS, brain stem reflex, respiratory status, and
degree of shivering are potential variables that can be
incorporated into a predictive model for a more precise
evaluation of brain injury in cardiac arrest survivors
undergoing TTM.
Table 1 FOUR score [19] with permission
Eye response
4 Eyelids open or opened, tracking, or blinking
to command
3 Eyelids open but not tracking
2 Eyelids closed but open to loud voice
1 Eyelids closed but open to pain
0 Eyelids remain closed with pain
Motor response
4 Thumbs-up, fist, or peace sign
3 Localizing to pain
2 Flexion response to pain
1 Extension response to pain
0 No response to pain or generalized
myoclonus status
Brainstem reflexes
4 Pupil and corneal reflexes present
3 One pupil wide and fixed
2 Pupil or corneal reflexes absent
1 Pupil and corneal reflexes absent
0 Absent pupil, corneal, and cough reflex
Respiration
4 Not intubated, regular breathing pattern
3 Not intubated, Cheyne–Stokes breathing pattern
2 Not intubated, irregular breathing
1 Breathes above ventilator rate
0 Breathes at ventilator rate or apnea
FOUR full outline of unresponsiveness
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Analgosedation for the targeted temperature management
Prevention of shivering during therapeutic hypothermia
Shivering is a centrally mediated thermoregulatory re-
sponse that usually initiates at approximately 35.5 °C
and is overcome below 34 °C. The management and pre-
vention of shivering is an important consideration dur-
ing TTM therapy. With preventing shivering and further
facilitating the induction of TTM, sedation and analgesia
play an important role in optimizing ventilator syn-
chrony and minimizing endogenous stress induced by
catecholamine surges. Inadequate sedation that allows
shivering is the most common cause of failure in achieving
or maintaining the target temperature.
Shivering is suppressed using a stepwise protocol during
TTM, and a clinical scale is used to quantify and assess it.
A suggested protocol based on the measurement of the
shivering index has been reported (Fig. 1) [24, 25].
However, there is no clear evidence to identify the pre-
ferred sedation and analgesia agents in TTM. Skin
counter-warming (warming of the non-cooled areas of
the skin) should be considered even when surface cool-
ing methods are used [13]. It was achieved by covering
the anterior surface (the hands, feet, and face) of the
patients with an air circulating blankets warmed to the
maximal temperature setting (43 °C) to reduce shivering
[26]. Shivering can be managed without the use of para-
lytic agents in most patients in the setting in ICU [13].
In comparison with benzodiazepines, propofol and dex-
medetomidine have desirable properties when continuous
infusions of sedative agents are required [27]. Doses of
both agents should be titrated to the desired effect, and
the rate of infusion should be accordingly adjusted. In
addition, the need for continuous infusions during the
maintenance phase, when shivering is less likely to occur,
should be evaluated [27]. If fentanyl is used in the main-
tenance phase of TTM, intensivists should be aware that
the rate of fentanyl elimination in humans does not trend
toward normal for at least 8 h during rewarming [28].
Fig. 1 Anti-shivering protocol example and the bedside shivering assessment scale. IV intravenous, PT per feeding tube, ECG electrocardiogram.
Modified from Brophy [24] and Badjatia [25] with permission
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Shivering following rewarming because of post-cardiac
arrest TTM is known to increase body temperature
(rebound pyrexia); marked pyrexia (median >38.7 °C)
was associated with a significantly lower proportion of
favorable outcome survivors (58 vs. 80 %) [29]. The
addition of a period of fever control (normothermia)
subsequent to TTM rewarming should be evaluated.
Neuromuscular blockade
The benefits and risks of neuromuscular blockade
(NMB) during TTM are controversial. Uncontrolled
shivering during TTM has been associated with a longer
time to achieve the target temperature; thus, uncon-
trolled shivering may adversely affect outcomes in
cardiac arrest survivors. NMB administration in TH
not only decreases refractory shivering but also facili-
tates both the rapid achievement and maintenance of
the target temperature. A recent report suggests that
continuous intravenous NMB therapy has a beneficial
effect on the survival of patients undergoing post-cardiac
arrest TH [30]. However, the same study also reported
that NMB therapy is associated with a non-significant
increase in the frequency of early-onset pneumonia [30].
Although continuous intravenous NMB is associated
with decreased mortality according to a study [31], the
association between NMB, TH, and outcomes must be
further analyzed in terms of shivering score (Fig. 1), NMB
usage, complications, and degree of brain damage [32].
However, NMB obscures convulsive activity, which
may be an important component in the neurological
evaluation. Continuous electroencephalography (EEG)
should be considered in comatose post-cardiac arrest pa-
tients, particularly if NMB is used [4]. In TTM, routine
and/or continuous NMB use is not supported [13] and
the duration of NMB should be kept to a minimum or
avoided altogether [4]. On the basis of pharmacokinetics
of NMB, it would be reasonable to use intermittent dosing




Traumatic brain injury (TBI) may cause disability and
death because of a combination of primary (shearing dam-
age to the neurons or glial cells at the time of impact) and
secondary (ischemia/hypoxia and reperfusion injury) brain
injuries [33]. For TBI, the specific effects of TH include
limiting the secondary brain injury by not only reducing
intracranial pressure (ICP) and cerebral metabolic de-
mands but also decreasing the disruption of the blood–
brain barrier, inhibiting the inflammatory cytokines,
and reducing free radicals related to reperfusion injury
[34–37].
Clinical trials have been conducted to investigate the
effects of mild TH (32–34 °C) on TBI, but they could
not demonstrate more favorable outcomes than those
demonstrated by the trials conducted to investigate the
effects of normothermia (37 °C) [38–40]. In Japan, a
multicenter RCT (brain hypothermia therapy for acute
head injury (BHYPO)) was conducted in patients with
severe TBI who received either mild TH (32.0–34.0 °C)
or underwent fever control (35.5–37.0 °C). The protocol
was well designed to improve former considerations
such as prolonged mild TH (more than 72 h), tight
hemodynamic monitoring, and slow rewarming [33, 38].
However, this study concluded that TH for severe TBI
did not improve the neurologic outcome or risk of
mortality [41].
The reason for the negative results obtained with TH
for TBI may have been the heterogeneity of the study
population, particularly pertaining to the age and degree
of primary brain damage. Yamamoto et al. [42] reported
an age limit of 50 years for TH to be effective in TBI.
The subanalysis of BHYPO, according to computed
tomography (CT) classification of the Traumatic Coma
Data Bank on admission [43], showed that favorable
outcomes at 6 months after injury in young patients
(≤50 years of age) with evacuated mass lesions signifi-
cantly increased from 33.3 % under fever control to
77.8 % under TH. Clifton [44] reported a similar post
hoc analysis of two randomized clinical trials [38, 39]
and showed that 41 % of patients requiring craniotomy
for hematoma treated with early hypothermia experienced
a poor outcome at 6 months after injury compared with
62 % of patients treated with late hypothermia or normo-
thermia, a 34 % reduction. Induction of hypothermia to
35 °C before or immediately after craniotomy, with main-
tenance at 33 °C for 48 h thereafter, may improve out-
comes of patients with severe TBI with surgically treated
hematomas [44].
Fever control (normothermia)
Conversely, the subanalysis of BHYPO, according to CT
classification of the Traumatic Coma Data Bank on ad-
mission [43], showed that patients with diffuse injury III
who were treated with TH had significantly high mortality
than those treated with fever control. Heterogeneity of the
TBI population is also expressed using Abbreviated Injury
Scale (AIS)-head scores, which describe TBI severity based
on a combination of symptoms, mechanisms (blunt or
penetrating), and radiographic findings (CT findings) [45].
The subanalysis of BHYPO, according to AIS-head scores
on admission [46], showed that the fever control group
demonstrated a significant reduction in mortality com-
pared with the mild TH group (9.7 vs. 34.0 %, p = 0.02)
pertaining to AIS 3 (serious) to 4 (severe) patients but not
AIS 5 (critical) patients. Recently, the Eurotherm3235 trial
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study reported that TH plus standard care for elevated
ICP provided a poor outcome for patients with TBI
compared with the outcome provided by standard care
alone [47].
TH influences all the organ systems, and any potential
benefit should be balanced against possible side effects
[48]. Several studies demonstrated that the rate of com-
plications significantly increased during prolonged mild
TH in patients with severe TBI [38–40, 49]. The manage-
ment approach for patients between post-cardiac arrest
and severe TBI may be different at temperatures below
35 °C because of multiple traumas associated with in-
creased mortality [50]. This may contribute to coagulopa-
thy, which usually occurs and persists for the first 24–48 h
[51]. Therefore, fever control may be better than mild TH
in terms of coagulopathy, which is specific for trauma pa-
tients. After the initiation of hypothermia in the BHYPO
study subanalysis [46], platelet counts decreased more in
the mild TH group than in the fever control group. In
TH for TBI, coagulopathy contributed to a further de-
generation of intracerebral lesion, which was the major
cause of death.
Intracranial pressure and the timing of therapeutic
hypothermia
The Eurotherm3235 trial reported that TH plus standard
care for elevated ICP provided a poor outcome in pa-
tients with TBI compared to the outcome provided by
standard care alone [47]. The key issue of TH for TBI is
the timing of TH. The Eurotherm3235 results [47] may
not be surprising because the elevation of ICP occurs
because of various destructive processes following im-
pact to the brain [52]. TH induction for subjects with
already elevated ICP may be too late for suppressing
these detrimental processes. In this study, significant
ICP reduction could not be achieved in the TH group.
Earlier induction of TH (before the elevation in ICP)
may mitigate harmful physiological consequences and
improve patient outcome. Another key issue of TH for
TBI is the target. Early induction of TH, particularly for
patients with evacuated intracranial hematomas, is re-
ported to be beneficial according to a post hoc analysis
of clinical trials in the USA [44] and Japan [43]. In
addition, physiological effects are considerably different
between 32 and 35 °C, and maintaining the temperature
at 32 °C may cause more adverse events. Therefore, a
detailed analysis on the introduction time and target
temperature is desirable.
Nonconvulsive status epilepticus and
electroencephalography monitoring
Overview
Status epilepticus (SE) is defined as 5 min or more of (i)
continuous clinical and/or electrographic or (ii) recurrent
seizure activity without recovery (returning to baseline)
between seizures [53]. The representative phenotype of
nonconvulsive SE (NCSE), which is often observed in the
intensive care setting, is acutely ill patients with severely
impaired/altered mental status, with or without subtle
motor movements (e.g., rhythmic muscle twitches or tonic
eye deviation that often occurs during acute brain injury)
[54–58]. NCSE in the ICU frequently follows uncontrolled
or partially treated generalized convulsive SE (GCSE).
Frequency of NCSE diagnosis increases significantly
after the implementation of continuous video-EEG mon-
itoring in ICU [59]. NCSE is a relatively common condi-
tion among patients with unexplained altered mental
status, with a prevalence of 8–37 % [54, 60]. In neuro
ICU, nonconvulsive seizures have been reported in 18–
34 % of patients who undergo EEG monitoring and 10 %
of them are NCSE patients [61–63]. The incidence of
NCSE in comatose survivors ranges from 12 to 24 %
[48, 64, 65]. Seizures following out-of-hospital cardiac
arrest have been linked to increased mortality [48, 64, 65].
NCSE should be diagnosed and treated rapidly to avoid
significant morbidity and mortality [66]. A retrospective
study of 100 NCSE patients identified the mortality rate to
be 18 % [66].
Continuous electroencephalography monitoring
A consensus panel at the 4th London-Innsbruck
Colloquium on SE and Acute Seizures held in Salzburg
(2013) proposed working criteria for the EEG diagnosis of
NCSE [67]. The American Clinical Neurophysiology
Society (ACNS) published proposals for Standardized
Critical Care EEG Terminology [68], which is now
widely used and has high interrater agreement [69].
Salzburg Consensus Criteria for diagnosis of Non-
convulsive Status Epilepticus (SCNC) implemented the
ACNS definitions for rhythmic delta activity to avoid
numerous false positives [70]. The ACNS criterion for
fluctuation further marginally reduces false positives
and in turn leads to a small loss of sensitivity.
There are many kinds of EEG which can be applied in
the ICU. Conventional EEG, which is a gold standard for
evaluating the neurologic function, only provides data
over a period of 30 min and requires highly trained
neurophysiologist to analyze it, whereas the aforemen-
tioned approach allows continuous monitoring by intensi-
vists immediately after the patient is assigned a hospital
bed [71].
Continuous EEG (cEEG) monitoring (over 24 h) is ne-
cessary to diagnose NCSE and to manage refractory SE
[72]. cEEG monitoring should be initiated within 1 h of
SE onset if ongoing seizures are suspected in all patients
[53]. cEEG monitoring should be done for at least 48 h
following acute brain insult in comatose patients to evalu-
ate nonconvulsive seizures and 24 h after the cessation of
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electrographic seizures or during antiepileptic drug (AED)
weaning trials [53].
Bedside simplified EEG monitoring, which comprised
from two-channel system, is a kind of cEEG. The appli-
cation of a two-channel simplified EEG has become
widespread in clinical practice [73] with seizure detec-
tion sensitivity directly being correlated with the number
of leads used. Using seven [74] and four leads [75]
yielded sensitivities of 93 and 68 %, respectively. Single-
channel EEG yields a sensitivity of 40 % [76]. The appli-
cation of bedside simplified EEG for the diagnosis of
NCSE may be limited to certain patients, particularly to
those at a risk of consciousness disturbances following
generalized convulsive status, recurrent coma, facial myo-
clonus, rapid involuntary eye movements, or aphasia [75].
Quantitative EEG may assist efficiently screening large
amounts cEEG data [77, 78]. Amplified-integrated EEG
(aEEG) monitoring is a well-developed type of quantita-
tive EEG. aEEG system is widely used to predict the out-
come of hypoxic ischemic encephalopathy in adults [79].
A bedside monitoring system combining aEEG and
simplified EEG was designed for the early diagnosis of
NCSE, which can then be confirmed by conventional
EEG because of the inherent low sensitivity of the sim-
plified EEG system [80]. Interpretation of aEEG and
simplified EEG traces requires some training to recognize
the patterns indicative of NSCE; these patterns are divided
into “rhythmicity,” “spike and wave,” and “periodicity” [68].
Subarachnoid hemorrhage
Advanced monitoring for circulation and delayed cerebral
ischemia
The occurrence of delayed cerebral ischemia (DCI) after
subarachnoid hemorrhage (SAH) increases poor neuro-
logic outcome [81] and the risk of DCI during hypovol-
emia that is frequently observed in SAH [82]. Neurogenic
pulmonary edema (PE), i.e., excess fluid accumulation in
the lungs, is another complication observed in SAH [83].
Neurogenic PE can produce severe hypoxemia, thereby
contributing to cerebral hypoxia in a brain that is already
vulnerable to secondary injury [84].
In a recent randomized trial [85], physician-directed
prophylactic triple-H administration was not associ-
ated with improved clinical outcomes or quantitative
hemodynamic indicators for intravascular volume. Fur-
thermore, the global end-diastolic volume index (GEDI),
measured using transpulmonary thermodilution method-
directed intervention studies, is warranted to better define
management algorithms for SAH patients with the aim of
preventing DCI. In a multicenter prospective cohort
study, for GEDI on days 1–7 after SAH, the optimal range
for fluid management according to the Cox proportional
hazards model was suggested to be 822–921 ml/m2 for
preventing the subsequent development of DCI and
pulmonary edema [86], even though the event of myocar-
dial stunning is not described. Mutoh et al. reported that
in comparison with standard less-invasive hemodynamic
therapy, early goal-directed therapy is beneficial for opti-
mizing the complex SAH-induced hemodynamic changes
during the therapy for DCI and in improving the prog-
nosis of patients with poor World Federation of Neuro-
surgical Societies grade or coexisting cardiopulmonary
complications [87].
Euvolemic fluid management is recommended in neu-
rocritical care, including SAH, even though fluid balance
[88] or central venous pressure [89] monitoring is not
standardized for targeting. Fluid management may ameli-
orate neurologic outcomes and decrease mortality associ-
ated with SAH, particularly by avoiding hypovolemia and
pulmonary edema.
Effect of neurocritical care/neuro-intensivists on outcome
Neurointensivists are physicians specially trained in neu-
rocritical care. Neurocritical care is one of the fellowship
subspecialties and board certified in the United Council
for Neurologic Subspecialties in the USA. Neurointensi-
vists assume the primary care role for his/her patients in
the ICU, coordinating both the neurological and medical
management of the patient.
The impact of neurocritical care/neuro-intensivists’ care
on outcomes in patients with life-threatening neurological
and neurosurgical illnesses has been reported by various
authors [90–95]. In particular, the proven efficacy of a
neurointensivist-managed neurocritical/intensive care unit
for patients with aneurysmal SAH has been frequently re-
ported. Neurointensivist-managed ICUs have reported
positive efficacy and outcomes for SAH patients per-
taining to their length of ICU stay [94, 96] and hospital
discharge status (home, rehabilitation facility, nursing
home, and death) [97]. However, there are no reported
studies demonstrating efficacy via direct functional out-
comes (i.e., good neurological outcomes at hospital
discharge) [96–98].
For SAH, in severe cases [Hunt and Hess grade III–V
subgroup], brain damage is severe and the efficacy of
neurocritical care is not precisely evaluated. Samuels et
al. reported that H&H grade I–III patients in a post-
neurointensive care group were significantly more likely
to be discharged home [97]. In addition, Knopf et al.
reported that the availability of a neurointensivist (but
not a neurocritical care unit) improved outcomes par-
ticularly in SAH patients with longer ICU and hospital
stays [98]. Literature demonstrated that the stated effica-
cies of neurocritical care in SAH patients were limited
to studies in the USA [1, 92, 94, 96–99].
Thus, neurointensivist management, particularly in
SAH patients, outside the USA should be evaluated to
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Sepsis-associated encephalopathy (SAE), which has also
been recently termed as sepsis-associated brain dysfunc-
tion (SABD), is a global brain dysfunction secondary to
the systemic inflammatory response to cerebral perfu-
sion and neuronal activity. It occurs because of infection
in the body and in the absence of a direct infection of
the central nervous system. Acute brain dysfunction
commonly occurs during sepsis and typically develops
early, often before the other organs are affected.
SAE involves a number of mechanisms, including neu-
roinflammation, wherein the interaction between cyto-
kines and neurotransmitters, particularly acetylcholine,
results in neuronal loss and alterations in cholinergic
signaling. There is no clear evidence to explain in detail
how inflammation reaches the brain during sepsis, but
inflammation occurs in the CNS early and later after sepsis
(both in laboratory animals and in humans). Moreover, the
interaction occurs in the periphery, accelerating a type of
immunosuppressive state.
Clinical, electrophysiological, and biochemical criteria
are used to diagnose SAE. However, the inability to
properly recognize the signs of SAE for diagnoses is a
major ongoing problem because septic patients are usu-
ally sedated, which masks neurologic disturbances.
Although its diagnosis is not specific in biochemistry
and imaging tests, it could potentiate severe outcomes,
including increased mortality, cognitive decline, progres-
sive immunosuppression, cholinergic anti-inflammatory
deficiency, and metabolic and hydroelectrolyte imbalance.
Therefore, bilateral communication between SAE and
multiple peripheral organs (particularly the immune
system) should be emphasized in sepsis management.
Examination to detect sepsis-associated brain dysfunction
Clinical symptoms of SAE are characterized by altered
mental status, i.e., alteration in consciousness ranging
from delirium or disorientation to coma, seizure, or focal
neurological signs. However, SAE or SABD overlaps with
delirium syndrome that is commonly associated with
critical illness.
A recent systemic review showed that the incidence of
EEG abnormalities during sepsis ranged from 12 to
100 % for background abnormalities and 6 to 12 % for
triphasic waves [100]. The aforementioned EEG abnor-
malities, including epileptiform discharges or electro-
graphic seizures, are associated with the presence and
severity of SAE/SABD. There is some evidence supporting
EEG use in the detection and prognostication of SAE
[100]. A recent study of ICU patients (35 % with sepsis)
found that time taken for burst suppression during coma
was an independent predictor of the prevalence of and
time to resolve post-coma/post-deep sedation ICU de-
lirium [101]. Considering the possible link between ex-
cess sedation use and SABD, the avoidance of burst
suppression using EEG monitoring may attenuate brain
dysfunction in sepsis patients.
Magnetic resonance imaging (MRI) in the acute phase
(7–14 days), including leukoencephalopathy and ische-
mic stroke, is associated with a poor prognosis in SAE
[102]. Other reports showed that these findings were
hardly specific to SAE [103], and a recent SAE case with
a favorable neurological outcome was reported in which
the authors showed severe encephalopathy with exten-
sive white matter lesions [104]. Taken together, it is con-
troversial whether MRI imaging changes noted in the
acute phase (7–14 days) are helpful in detecting SAE. A
recent study showed that a longer duration of delirium
was strongly associated with a greater extent of brain at-
rophy as well as white matter disruption on advanced
MRI scan performed at hospital discharge and 3-month
follow-up [105].
Using transcranial Doppler ultrasound to estimate
cerebral blood flow, a recent report showed that alter-
ations in the autoregulation of cerebral blood flow can
persist for several days in >40 % patients with septic
shock [106] and that cerebral vasoconstriction on the
first day of sepsis diagnosis implied the development of
neurological symptoms independent of the age and
APACHE II score [107].
As serum biomarker for prognosis, serum S100beta
concentrations were significantly higher in patients with
sepsis-associated brain dysfunction than in normal con-
trols and correlated directly to GCS [108].
The diagnosis of SAE or SABD usually depends on
case history and clinical symptom and may be affected
by sedation and intubation. For early diagnosis and
evaluation of severity of SAE or SABD, neuromonitoring
using EEG, MRI, transcranial Doppler ultrasound, and
serum biomarker may be helpful.
Conclusions
Neurocritical care provides comprehensive neurological
support for patients with life-threatening neurological
and neurosurgical illnesses by integrating and balancing
the management of both the brain and the other organs.
New therapies that address the underlying pathophysiology
are required to improve neurologic outcomes.
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